[go: up one dir, main page]

AR066155A1 - Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia - Google Patents

Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia

Info

Publication number
AR066155A1
AR066155A1 ARP080102438A ARP080102438A AR066155A1 AR 066155 A1 AR066155 A1 AR 066155A1 AR P080102438 A ARP080102438 A AR P080102438A AR P080102438 A ARP080102438 A AR P080102438A AR 066155 A1 AR066155 A1 AR 066155A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
nhc
conh
nhso2
Prior art date
Application number
ARP080102438A
Other languages
English (en)
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of AR066155A1 publication Critical patent/AR066155A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de formula (1) poseen una afinidad de enlace significativamente baja con receptores tiroideos y por lo tanto carecen de manera considerable de efectos tirotoxicos. También se refiere al uso del compuesto de formula (1) para la preparacion de un medicamento para tratar diversas afecciones patologicas tales como obesidad, dislipidemia, síndrome metabolico y co-morbilidades asociadas con síndrome metabolico. Reivindicacion 1: Un compuesto de formula (1) donde, R1 y R3 son iguales o diferentes y son seleccionados de manera independiente de H, alquilo C1-6, cicloalquilo C3-7, halo, CN, CF3, -O-alquilo C1-6, -CO2-alquilo C1-6, -COOH, -CONH-alquilo C1-6, -CONH-arilo, -NH2, -CONH-R6, -CONR5, -alquil C1-3-arilo, -alquilo C1-3-R6, -NH-alquilo C1-6, -NH-arilo, -NH-SO2-alquilo C1-6, -CH2NH-alquilo C1-6, -CH2-O-alquilo C1-6, -alquil C1-3-NR5, R6, R7, donde alquilo C1-6 y cicloalquilo C3-7 están sustituidos en forma opcional con uno o mas sustituyentes seleccionados de alquilo C1-6, halo, ciano, -OH, oxo, -COOH, -O-alquilo C1-6, -O-bencilo, -COO-alquilo C1-6, -CONH-alquilo C1-6, -CONR5, -CONH-arilo, -CONH-heteroarilo o -CH2NR5; R2 se selecciona de alquilo C1-6, cicloalquilo C3-6, alquenilo C3-6, alquinilo C3-6, -C(O)-alquil C1-3-COOH, -alquil C1-3-COOH, -C(O)-alquil-C1-3-COO-alquilo, -C(O)-C(O)O-alquilo C1-6, -C(O)-alquil- C1-3-NH-alquilo C1-6, -C(O)-O-alquilo C1-6, -C(O)NR5, -C(O)NH-alquilo C1-6, -C(O)-alquilarilo C1-3, -C(O)-alquil C1-3-R6, R6, R7, donde dicho alquilo C1-6, cicloalquilo C3-6, alquenilo C3-6, alquinilo C3-6 están sustituidos en forma opcional con uno o más sustituyentes seleccionados de perhaloalquilo, oxo, -C(O)OH, -C(O)-O-alquilo C1-3, -C(O)-O-alquil C1-3-arilo, -C(O)-O-alquil C1-3-R6, -CONH2, -CONH-alquilo C1-3, -C(O)NH-arilo, -C(O)NH-R6, -CONR5, -CONHNH2, -C(=NH)NH-alquilo C1-6, -C(=NH)NH2, C(=NH)NHOH, -C(O)-R8, -C(O)NHSO2-alquilo C1-6, -C(O)NHSO2-arilo, -C(O)NHOH, -C(O)NHSO2-R6, -C(O)NHNH-alquilo C1-6, -C(O)NHNH-arilo, -CONH-alquil C1-2-arilo, -C(O)NH-alquil C1-2-R6, -CH2NR5, -NH2, -NH-alquilo C1-6, -NH-C(O)-O-alquilo C1-3, -NH-C(O)-alquilo C1-3, -NHC(O)-arilo, -NHC(O)-alquilarilo C1-3, -NHC(O)-R6, -NH-C(O)NR5, -NH-C(O)NH-arilo, -NHC(O)NH-alquilo C1-6, -NHSO2-alquilo C1-6, -NH-SO2-arilo, -NH-SO2-R6, halo, ciano, -OH, -O-alquilo C1-6, -O-arilo, -O-heteroarilo, -O-alquil-C1-2-arilo, -SO3H, -SO2NH-arilo, -SO2NH-R6 o -SO2NH-alquilo C1-6, R6 o R7; R5 junto con el átomo de nitrogeno al que está unido forman un anillo saturado o insaturado de C3-6 miembros, que puede contener además 1-2 heteroátomos seleccionados de O, N o S y puede estar sustituido opcionalmente con uno o más sustituyentes seleccionados de oxo, -COOH, halo, -OH, -O-alquilo C1-6, o -alquilo C1-6; R6 se selecciona de fenilo o heteroarilo de 5-8 miembros que contiene 1-4 heteroátomos seleccionados de O, N o S, donde dicho anillo heteroarilo o fenilo están sustituidos en forma opcional con uno o más sustituyentes seleccionados de halogeno, -OH, -O-alquilo C1-6, -perhaloalquilo, -alquilo C1-6, -cicloalquilo C3-6, -SO2-alquilo C1-6, ciano, -COOH, -C(O)O-alquilo C1-6, -C(O)O-CH2-arilo, -C(O)O-arilo, -CONH-alquilo C1-3, nitro, -NH2, -NH-alquilo C1-6, -NHC(O)-alquilo C1-6, -NHC(O)-arilo, -NHSO-alquilo C1-6, -CONH2, -SO2-alquilo C1-6, -NHSO2-alquilo C1-6 o -COR8; R7 es un anillo heterocíclico de 3-6 miembros que contiene 1-4 heteroátomos seleccionados de O, N o S, y el mencionado anillo heterocíclico está sustituido opcionalmente con uno o más sustituyentes seleccionado de oxo, halogeno, -O-alquilo C1-6, -OH, -CF3, alquilo C1-6, cicloalquilo C3-6, ciano, -COOH, -C(O)O-alquilo C1-6, -C(O)O-CH2-arilo, -C(O)O-arilo, -NH2, -NH-alquilo C1-6, -NHC(O)-alquilo C1-6, -NHC(O)-arilo, -CONH2, -SO2-arilalquilo C1-6, -SO2-alquilo C1-6, -NHSO2-alquilo C1-6 o -COR8; R8 es un aminoácido que está enlazado a través de su átomo de nitrogeno; Z = O, CH2 o NH; R4 se selecciona de las formulas P, Q o T; R9 se selecciona de -OH, -O-alquilo, -OSO3H, halogeno, -C(O)O-alquilo C1-6, -C(O)NHR8, -OC(O)-alquilo C1-6, -O-perhaloalquilo, -OC(O)O-alquilo C1-6, -CONR5 , -NHCO-alquilo C1-6, -NHC(O)-O-alquilo C1-6, -NHC(O)-O-arilo, -NHSO2-alquilo C1-6, -NHSO2-arilo, -NHCONR5 o de formula (2); R10 se selecciona de H, halogeno, alquilo C1-6, alcoxi, ariloxi, -NHCO-alquilo C1-6, -NHSO2-alquilo C1-6 o -NH-SO2-arilo; R11 es -CO-alquilo C1-6, -SO2-alquilo C1-6 o -SO2-arilo; G' se selecciona de H, halogeno o alquilo C1-6; G'' se selecciona de hidrogeno, alquilo C1-6, cicloalquilo C3-6, arilo, halogeno, perhaloalquilo, CN, CHO, -alquilarilo-C1-3, -alquil C1-6-O-alquilo C1-6, -CH2R9, -CH2-arilo, -CH2NR5, -COOH, -C(O)O-alquilo C1-6, -CONH-alquilo C1-6, -CONR5, -SO2NR5, -SO2NH-alquilo C1-6, -SO2NH-arilo; n puede ser uno o dos; incluyendo sus sales aceptables para uso farmacéutico y sus hidratos, solvatos, atropisomeros, regioisomeros, enantiomeros, diasteromeros, tautomeros, polimorfos y profármacos de los mismos, con la salvedad que: cuando R4 es Q entonces R2 es diferente de R6 y R7; incluyendo sus sales aceptables para uso farmacéutico y sus hidratos, solvatos, atropisomeros, regioisomeros, enantiomeros, diasteromeros, tautomeros, polimorfos y profármacos de los mismos.
ARP080102438A 2007-06-06 2008-06-06 Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia AR066155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN857KO2007 2007-06-06

Publications (1)

Publication Number Publication Date
AR066155A1 true AR066155A1 (es) 2009-07-29

Family

ID=39828965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102438A AR066155A1 (es) 2007-06-06 2008-06-06 Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia

Country Status (26)

Country Link
US (2) US8143424B2 (es)
EP (1) EP2061766B1 (es)
JP (1) JP5243537B2 (es)
KR (1) KR101152965B1 (es)
CN (1) CN101772487B (es)
AR (1) AR066155A1 (es)
AT (1) ATE478053T1 (es)
AU (1) AU2008259314B2 (es)
CA (1) CA2698704C (es)
CY (1) CY1110925T1 (es)
DE (1) DE602008002205D1 (es)
DK (1) DK2061766T3 (es)
EA (1) EA019084B1 (es)
ES (1) ES2351274T3 (es)
HR (1) HRP20100611T1 (es)
IL (1) IL202515A (es)
MX (1) MX2009013070A (es)
NZ (1) NZ582273A (es)
PL (1) PL2061766T3 (es)
PT (1) PT2061766E (es)
RS (1) RS51501B (es)
SI (1) SI2061766T1 (es)
TW (1) TWI360541B (es)
UA (1) UA98962C2 (es)
WO (1) WO2008149379A2 (es)
ZA (1) ZA200908760B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724381B2 (en) * 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
JP5778755B2 (ja) * 2010-04-15 2015-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヒドロキノンの製造方法
US8877795B2 (en) * 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
FI4406594T3 (fi) 2012-09-17 2025-11-26 Madrigal Pharmaceuticals Inc Kilpirauhashormonin analogeja
HUE052080T2 (hu) 2013-09-09 2021-04-28 Peloton Therapeutics Inc Ariléterek és azok felhasználásai
WO2015095048A1 (en) 2013-12-16 2015-06-25 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
CN103992225B (zh) * 2014-03-26 2016-01-13 安徽师范大学 一种水杨醛衍生物及其制备方法
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
WO2016066664A1 (en) * 2014-10-31 2016-05-06 F. Hoffmann-La Roche Ag New pyridinyloxy- and phenyloxy-pyrazolyl compounds
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2017084995A1 (en) * 2015-11-16 2017-05-26 Lonza Ltd Method for preparation of 1-methyl-3-(trifluoromethyl)-1hpyrazol-5-ol
RU2621163C1 (ru) * 2016-02-16 2017-05-31 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Антифибролитическое средство
CN110167557A (zh) 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
CA3051357A1 (en) 2017-02-17 2018-08-23 Eidos Therapeutics, Inc. Processes for preparing 3-(3-(3,5-dimethyl-1h-propoxy)-4-fluorobenzoic acid, its intermediates, and salts thereof
TWI817999B (zh) 2018-03-23 2023-10-11 美商文涵治療有限公司 使用ag10治療ttr澱粉樣沉積症之方法
PT3836920T (pt) 2018-08-17 2025-12-02 Eidos Therapeutics Inc Formulações de ag10
WO2020058945A1 (en) * 2018-09-22 2020-03-26 Torrent Pharmaceuticals Limited Methods of producing pyrazole compounds
KR102396602B1 (ko) * 2019-02-28 2022-05-11 주식회사 마더스제약 피라졸 아마이드 유도체 화합물 및 이의 용도
WO2023047203A1 (en) 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
CN116063296B (zh) * 2021-11-02 2025-08-19 凯思凯迪（上海）医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
EP4482487A1 (en) * 2022-02-23 2025-01-01 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators
CA3244850A1 (en) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. PYRAZOLYL COMPOUNDS USED AS KV7 CHANNEL ACTIVATORS
JP2025507542A (ja) * 2022-02-23 2025-03-21 バイオヘイブン・セラピューティクス・リミテッド Ｋｖ７チャネル活性化剤としてのピラゾリル化合物
CN116836158A (zh) * 2022-03-23 2023-10-03 凯思凯迪（上海）医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN114920635B (zh) * 2022-04-29 2023-05-12 郑州原理医药研究院有限公司 4-羟基-1-茚酮的制备方法
AR129535A1 (es) 2022-06-21 2024-09-04 Syngenta Crop Protection Ag Derivados de carboxamida heterocíclicos bicíclicos microbiocidas
EP4608836A1 (en) 2022-10-27 2025-09-03 Syngenta Crop Protection AG Microbiocidal heterobicyclic dihydrooxadiazine derivatives
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7598596A (en) 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
ES2208812T3 (es) 1997-02-25 2004-06-16 Akzo Nobel N.V. Derivados de azetidina y de pirrolidina.
TR200002466T2 (tr) 1998-02-26 2000-12-21 Akzo Nobel N.V. Azetidin ve pirolidin türevleri
US6240678B1 (en) 1998-07-09 2001-06-05 Karl Heinz Spether Capping head with torque adjustment
SK12102001A3 (sk) 1999-03-01 2002-10-08 Pfizer Products Inc. Oxámové kyseliny a ich deriváty ako ligandy tyreoidného receptora
MXPA01012492A (es) 1999-06-01 2002-07-02 Univ Texas Southwestern Med Ct Metodo para tratar la perdida capilar.
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
WO2003016286A1 (fr) 2001-08-17 2003-02-27 Sankyo Agro Company, Limited Derive de 3-phenoxy-4-pyridazinol et composition herbicide le contenant
WO2003064369A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
WO2006128056A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
GB0513692D0 (en) * 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
DE602006016821D1 (de) * 2005-07-21 2010-10-21 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon-rezeptoragonisten
CA2620425A1 (en) 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes

Also Published As

Publication number Publication date
US8143424B2 (en) 2012-03-27
CN101772487A (zh) 2010-07-07
DE602008002205D1 (de) 2010-09-30
EA200901651A1 (ru) 2010-12-30
IL202515A (en) 2013-07-31
WO2008149379A2 (en) 2008-12-11
AU2008259314A1 (en) 2008-12-11
EA019084B1 (ru) 2014-01-30
CN101772487B (zh) 2014-01-22
DK2061766T3 (da) 2010-12-13
US8378118B2 (en) 2013-02-19
WO2008149379A3 (en) 2009-03-19
CA2698704C (en) 2016-01-19
AU2008259314B2 (en) 2011-05-19
CA2698704A1 (en) 2008-12-11
TWI360541B (en) 2012-03-21
CY1110925T1 (el) 2015-06-10
HRP20100611T1 (hr) 2010-12-31
NZ582273A (en) 2011-06-30
SI2061766T1 (sl) 2010-12-31
PL2061766T3 (pl) 2011-02-28
UA98962C2 (ru) 2012-07-10
KR101152965B1 (ko) 2012-06-08
RS51501B (sr) 2011-04-30
MX2009013070A (es) 2010-01-29
EP2061766B1 (en) 2010-08-18
ES2351274T3 (es) 2011-02-02
HK1129221A1 (en) 2009-11-20
JP2010529108A (ja) 2010-08-26
JP5243537B2 (ja) 2013-07-24
ZA200908760B (en) 2010-08-25
IL202515A0 (en) 2010-06-30
PT2061766E (pt) 2010-11-26
ATE478053T1 (de) 2010-09-15
TW200911756A (en) 2009-03-16
US20120202816A1 (en) 2012-08-09
KR20100022104A (ko) 2010-02-26
US20100168110A1 (en) 2010-07-01
EP2061766A2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20190329A1 (es) Compuestos moduladores de fxr (nr1h4)
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
AR059516A1 (es) Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
AR092568A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
AR091285A1 (es) Inhibidores de bromodominio y sus usos
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR044005A1 (es) Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden
AR079486A1 (es) Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas.
AR077463A1 (es) Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
EA201170096A1 (ru) Замещенные производные пиримидона
PE20070172A1 (es) DERIVADOS BICICLICOS COMO INHIBIDORES DE p38
AR090670A1 (es) Compuestos herbicidas
AR067058A1 (es) Oxazolidinonas sustituidas y su uso para preparar medicamentos
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FG Grant, registration